University of Pennsylvania (UPenn)

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">University of Pennsylvania (UPenn)</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>UPenn Seal</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Philadelphia, PA, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Ivy League Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1740</td>
</tr>
<tr>
<td class="label">Students</td>
<td>~25,000</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.upenn.edu/" target="_blank">upenn.edu</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, TDP-43</td>
</tr>
<tr>
<td class="label">Key Center</td>
<td>Center for Neurodegenerative Disease Research (CNDR)</td>
</tr>
</table>

University of Pennsylvania (UPenn)

Introduction

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">University of Pennsylvania (UPenn)</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>UPenn Seal</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Philadelphia, PA, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Ivy League Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1740</td>
</tr>
<tr>
<td class="label">Students</td>
<td>~25,000</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.upenn.edu/" target="_blank">upenn.edu</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, TDP-43</td>
</tr>
<tr>
<td class="label">Key Center</td>
<td>Center for Neurodegenerative Disease Research (CNDR)</td>
</tr>
</table>

University of Pennsylvania (UPenn)

Introduction

The University of Pennsylvania is an Ivy League research university located in Philadelphia, Pennsylvania. Founded in 1740, Penn is one of the oldest and most prestigious universities in the United States, with a distinguished history of contributions to medicine and science. The university's Center for Neurodegenerative Disease Research (CNDR) is one of the oldest and most distinguished centers for neurodegenerative disease research in the United States, having been founded in the 1970s. Penn has been instrumental in defining the pathological hallmarks of Alzheimer's disease and pioneering approaches to understanding proteinopathies across multiple neurodegenerative conditions.

The institution hosts leading researchers in neurodegeneration research and maintains comprehensive programs spanning [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), and [frontotemporal dementia](/diseases/frontotemporal-disease). Research programs at Penn have contributed to both basic science understanding and translational approaches for neurodegenerative conditions, making significant contributions to biomarker development, neuropathology, and therapeutic research.

History and Institutional Milestones

Founding and Early Development

The University of Pennsylvania traces its origins to 1740, making it one of the oldest universities in the United States. The Perelman School of Medicine, established in 1765, was the first medical school in the colonies and has been a leader in medical research and education for over 250 years.

Center for Neurodegenerative Disease Research (CNDR)

The CNDR was founded in 1977 by Dr. John Q. Trojanowski, establishing Penn as a global leader in neurodegeneration research. The center has maintained continuous NIH funding for over four decades and has trained generations of researchers who have gone on to lead neurodegeneration programs worldwide.

Key Historical Milestones

• 1977: CNDR founded by Dr. John Trojanowski
• 1980s: CERAD criteria established for AD neuropathological diagnosis
• 1990s: Discovery of tau and alpha-synuclein aggregation mechanisms
• 2000s: TDP-43 identified as the protein linking ALS and FTD
• 2010: Penn Alzheimer's Disease Research Center established (NIH-funded)
• 2015: Leadership in NIH AMP-AD consortium
• 2020: Novel therapeutic targets for neurodegeneration identified

Research Programs

Center for Neurodegenerative Disease Research (CNDR)

The CNDR serves as the hub for neurodegeneration research at Penn, encompassing multiple research themes:

Neuropathology Program

• Defining disease staging systems for AD, PD, and ALS
• Biochemical characterization of protein aggregates
• Human brain tissue research using extensive brain bank resources

• CSF biomarker development for early detection
• Blood-based biomarker assays using ultra-sensitive technologies
• Imaging biomarkers for disease progression monitoring

• Antibody therapeutics for tau and alpha-synuclein
• Gene therapy approaches using AAV vectors
• Small molecule modulators of protein aggregation

Penn Alzheimer's Disease Research Center

The Penn ADRC, funded by the NIA, provides:

• Clinical research infrastructure for AD studies
• Longitudinal cohort follow-up
• Brain bank with detailed neuropathological characterization
• Training program for clinical researchers

Institute on Aging

The Institute on Aging coordinates aging-related research across the university, integrating basic science, clinical research, and patient care programs.

Major Discoveries and Contributions

CERAD Criteria

Penn researchers developed the CERAD (Consortium to Establish a Registry for Alzheimer's Disease) neuropathological criteria in the 1980s, which became the worldwide standard for diagnosing Alzheimer's disease at autopsy. This work established standardized protocols for assessing amyloid plaques and neurofibrillary tangles that are still in use today.

TDP-43 Discovery

In the 2000s, Penn researchers made the groundbreaking discovery that TDP-43 is the protein that forms inclusions in ALS and FTD [@trojanowski2022; @neumann2023]. This finding revolutionized understanding of these diseases and opened new therapeutic avenues. Prior to this discovery, the protein aggregating in most ALS and FTD cases was unknown.

Alpha-Synuclein Research

Penn has been a leader in understanding alpha-synuclein aggregation and propagation in [Parkinson's disease](/diseases/parkinsons-disease) [@lee2019; @singleton2023]:

• Discovery of alpha-synuclein as the main component of Lewy bodies
• Development of RT-QuIC (real-time quaking-induced conversion) assay for alpha-synuclein detection
• Understanding of prion-like propagation mechanisms

Biomarker Development

Penn researchers have pioneered biomarker development for neurodegenerative diseases [@shaw2023; @kelley2023]:

• CSF biomarkers for AD (Aβ42, total tau, phosphorylated tau)
• Blood neurofilament light chain as a marker of neuronal damage
• Development of ultra-sensitive Simoa assays
• Novel biomarker discovery through proteomic approaches

Tau Therapeutics

Penn has led efforts to develop tau-based therapeutics [@brunden2024; @goedert2024]:

• First-in-human trials of tau immunotherapy
• Understanding of tau propagation mechanisms
• Development of small molecule inhibitors

Key Researchers and Their Contributions

Founding Leadership

John Q. Trojanowski, MD, PhD (Co-Director, CNDR)

• Discovery of TDP-43 pathology in ALS and FTD
• Development of CERAD neuropathological criteria
• Contributions to understanding tau pathology
• Over 900 publications in neurodegeneration research

• Discovery of alpha-synuclein in Lewy bodies
• Understanding of protein aggregation mechanisms
• Development of aggregate detection assays
• Leadership in therapeutic development programs

Current Faculty

Leslie M. Shaw, PhD

• Biomarker development and validation
• Leadership in CSF biomarker standardization
• Contributions to ADNI and AMP-AD consortia

• Tau therapeutic development
• Small molecule drug discovery
• Preclinical validation of therapeutic candidates

Additional Faculty

• John E. Duda: Neuropathology and Lewy body research
• Edward B. Lee: TDP-43 biology
• Alessandro R. F.: Neuroinflammation research

Disease-Specific Research Programs

Alzheimer's Disease

Penn maintains a comprehensive Alzheimer's disease research program [@goldman2024; @kelley2023; @chen2023]:

Basic Science

• Amyloid and tau pathology mechanisms
• APOE biology and genetic risk factors
• Neuroinflammation contributions
• Synaptic dysfunction in disease

• CSF Aβ42, t-tau, p-tau181, p-tau217
• Blood p-tau assays
• PET imaging for amyloid and tau

• Penn ADRC longitudinal cohort
• Clinical trials for disease-modifying therapies
• Early detection and prevention studies

Parkinson's Disease

The Parkinson's disease research program encompasses [@singleton2023; @bordelon2024; @farrer2024]:

Alpha-Synuclein Research

• Formation and propagation of Lewy bodies
• Strain diversity in alpha-synuclein aggregates
• Seeding and templating mechanisms

• LRRK2 biology and therapeutic targeting
• GBA variant contributions to PD risk
• Gene-environment interactions

• Movement disorders program
• Deep brain stimulation optimization
• Clinical trials for novel therapeutics

ALS and Motor Neuron Disease

Penn has a robust program in motor neuron disease research [@trojanowski2022; @neumann2023; @traynor2022]:

TDP-43 Biology

• Discovery of TDP-43 pathology in ALS and FTD
• Understanding of RNA metabolism defects
• Liquid-liquid phase separation in disease

• C9orf72 repeat expansion mechanisms
• SOD1 and FUS biology
• Genetic risk factor discovery

• Novel drug candidates targeting aggregation
• Gene therapy approaches
• Clinical trial participation

Frontotemporal Dementia

Research on FTD includes [@seeley2024; @neumann2023]:

• FTLD-tau subtypes: CBD, PSP, and others
• FTLD-TDP: Understanding TDP-43 proteinopathy
• Genetics: C9orf72 and other genetic causes

Research Infrastructure

Brain Bank and Tissue Resources

Penn maintains one of the largest and most well-characterized brain banks in the world:

• Tissue Collection: Comprehensive sampling from all major brain regions
• Clinical Correlation: Detailed clinical histories for each case
• Standardized Assessment: Uniform neuropathological evaluation using CERAD protocols
• Distribution Program: Tissue sharing with researchers worldwide

Core Facilities

Neuropathology Core

• Histopathology and tissue processing
• Molecular pathology and genetic characterization
• Immunohistochemistry and special stains

• CSF biomarker measurements
• Ultra-sensitive blood biomarker assays
• PET and MRI image analysis

• Phase I-III clinical trials infrastructure
• Patient registry and longitudinal cohorts
• Data management and statistical support

Clinical Programs

Memory Disorders Clinic

• Comprehensive diagnostic evaluation
• Access to clinical trials
• Caregiver support and education

• Medication optimization
• Deep brain stimulation evaluation
• Rehabilitation services

Training and Education

Graduate Programs

Penn offers comprehensive training in neurodegeneration research:

• Neuroscience Graduate Group: Interdisciplinary PhD program
• MD/PhD Program: Combined clinical and research training
• Master's Programs: Research and clinical master's degrees

Clinical Training

• Neurology Residency: ACGME-accredited program
• Movement Disorders Fellowship: Sub-specialty training
• Neuropathology Fellowship: Diagnostic training
• Memory Disorders Fellowship: Clinical research training

Funding and Support

Major Grants

• NIH Alzheimer's Disease Research Center (P50)
• Multiple R01 and U01 grants from NIA and NINDS
• ALS Association research support
• Michael J. Fox Foundation grants
• Alzheimer's Association funding

Collaborative Programs

• National Alzheimer's Coordinating Center (NACC)
• AMP-AD Consortium
• International Neuropathology Consortium

International Collaborations

Penn leads and participates in major collaborative studies:

• ACT Consortium: Clinical trials network
• International FTD Consortium: Global FTD research
• IPDGC: International Parkinson's Disease Genetics Consortium

Future Directions

Emerging Research Areas

Strategic Priorities

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [Tau Protein](/proteins/tau)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [TDP-43](/proteins/tdp-43)
• [Harvard University](/institutions/harvard-university)
• [Columbia University](/institutions/columbia-university)
• [MIT](/institutions/mit)

External Links

• [University of Pennsylvania](https://www.upenn.edu)
• [Perelman School of Medicine](https://www.med.upenn.edu)
• [Center for Neurodegenerative Disease Research](https://www.med.upenn.edu/cndr)
• [Penn Alzheimer's Disease Research Center](https://www.pennadc.org)

References